Screener
Capricor Therapeutics CAPR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | March 31, 2026 / (unaudited) | December 31, 2025 | December 31, 2025 |
|---|---|---|---|
| CURRENT ASSETS | |||
| Cash and cash equivalents | $105,421,484 | $ | $287,847,312 |
| Marketable securities | 173,188,430 | 30,281,603 | |
| Receivables | — | 59,167 | |
| Prepaid expenses and other current assets | 4,478,895 | 4,751,674 | |
| TOTAL CURRENT ASSETS | 283,088,809 | 322,939,756 | |
| PROPERTY AND EQUIPMENT, net | 28,502,617 | 18,312,238 | |
| OTHER ASSETS |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's cash & equivalents?
- Capricor Therapeutics (CAPR) reported cash & equivalents of $105.42M in Q1 2026.
- How has Capricor Therapeutics's cash & equivalents changed year-over-year?
- Capricor Therapeutics's cash & equivalents increased by 266.1% year-over-year, from $28.79M to $105.42M.
- What is the long-term trend for Capricor Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Capricor Therapeutics's cash & equivalents has grown at a 54.5% compound annual growth rate (CAGR), from $32.67M to $287.85M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Capricor Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude